COVID-19 Vaccine & Blood Clots: Fact Check

Recent claims circulating online suggest a recent study proves the COVID-19 vaccine causes blood clots. This represents inaccurate. A fact-check by AFP Factuel clarifies that the study, published in the journal Blood, actually sheds light on the mechanisms behind a very rare blood clotting side effect linked to initial COVID-19 vaccines – specifically those developed by Johnson & Johnson (J&J) and AstraZeneca – which are now largely discontinued. The research does not demonstrate a causal link with currently administered vaccines.

Understanding Vaccine-Associated Thrombosis

The rare but serious side effect in question is called vaccine-induced immune thrombocytopenia with thrombosis (VITT). VITT involves both blood clots (thrombosis) and low platelet counts (thrombocytopenia). It gained attention early in the vaccine rollout, primarily with the adenovirus vector vaccines from J&J and AstraZeneca. These vaccines used a modified adenovirus – a common cold virus – to deliver genetic material instructing the body to produce a harmless piece of the SARS-CoV-2 spike protein, triggering an immune response.

The new research, detailed in Techno-Science.net, focuses on the role of platelet factor 4 (PF4), a chemical released by platelets. Researchers discovered that, in rare instances, the body produces antibodies against PF4 after vaccination with these earlier vaccines. These antibodies then trigger an exaggerated clotting response. This discovery isn’t about current vaccines; it’s about understanding why this rare event occurred with specific, older vaccine technologies.

Current Vaccines and Blood Clot Risk

It’s crucial to distinguish between the initial vaccines and those currently in widespread use. The vast majority of COVID-19 vaccines now administered globally, including those from Pfizer and Moderna, utilize mRNA technology. MSN reports that these mRNA vaccines have not been linked to the same VITT syndrome observed with the adenovirus vector vaccines. The mechanism of action is fundamentally different, and the risk profile is distinct.

While any vaccine carries a very modest risk of side effects, the benefits of COVID-19 vaccination continue to far outweigh the risks. The risk of serious complications, including blood clots, is significantly higher from contracting COVID-19 itself than from receiving the vaccine.

Putting the Risk into Perspective

Understanding risk requires context. Thrombosis Canada provides educational materials on blood clots, noting that they are not frequent in the general population. The incidence of VITT following the J&J and AstraZeneca vaccines was estimated to be around 1 in 200,000 vaccinations, a very rare occurrence. To set this in perspective, the risk of developing a blood clot from COVID-19 infection is considerably higher – studies have shown an increased risk of thrombosis in the weeks following a COVID-19 diagnosis.

What the Research Doesn’t Present

The study in Blood does not establish a link between mRNA vaccines (Pfizer, Moderna) and VITT. It does not suggest that current vaccination strategies are unsafe. The research is valuable because it deepens our understanding of the immunological processes that can, in rare cases, lead to blood clots following vaccination with specific types of vaccines. It’s important to remember that correlation does not equal causation. The study identifies a mechanism, but it doesn’t imply that the mechanism is broadly applicable to all COVID-19 vaccines.

The Role of Ongoing Surveillance

Public health agencies worldwide continue to monitor vaccine safety through robust surveillance systems. These systems track adverse events following vaccination, allowing for the early detection of any potential safety signals. The initial detection of VITT was a direct result of this ongoing surveillance. Data from these systems are regularly reviewed by expert panels, such as the Vaccine Adverse Event Reporting System (VAERS) in the United States and similar programs in Canada and Europe.

Guidance Updates and Vaccine Strategies

The identification of VITT led to adjustments in vaccine strategies. In some regions, recommendations were updated to prioritize mRNA vaccines over the adenovirus vector vaccines, particularly for younger individuals where the risk of VITT was slightly higher. These decisions were based on a careful assessment of the risks and benefits of each vaccine option.

What Comes Next: Continued Research and Monitoring

The research into VITT and the mechanisms underlying vaccine-associated thrombosis is ongoing. Scientists are continuing to investigate the factors that contribute to the development of these rare blood clots, with the goal of improving vaccine safety and developing more effective treatments. Further studies are needed to fully understand the long-term effects of COVID-19 vaccination and to monitor the ongoing safety profile of all available vaccines. Public health authorities will continue to update guidance as new evidence emerges.